MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Search

Prestige Consumer Healthcare

Fechado

SetorSaúde

57.88 1.56

Visão Geral

Variação de preço das ações

24h

Atual

Mín

57.18

Máximo

57.91

Indicadores-chave

By Trading Economics

Rendimento

4.5M

47M

Vendas

9.3M

283M

P/E

Médio do Setor

14.997

63.808

Margem de lucro

16.475

Funcionários

600

EBITDA

-6.8M

80M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+40.84% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-487M

2.7B

Abertura anterior

56.32

Fecho anterior

57.88

Sentimento de Notícias

By Acuity

50%

50%

150 / 348 Ranking em Healthcare

Prestige Consumer Healthcare Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de abr. de 2026, 20:26 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 de abr. de 2026, 18:15 UTC

Notícias Principais

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 de abr. de 2026, 16:49 UTC

Notícias Principais

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

18 de abr. de 2026, 01:00 UTC

Notícias Principais

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17 de abr. de 2026, 22:58 UTC

Ganhos

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 de abr. de 2026, 21:32 UTC

Conversa de Mercado

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 de abr. de 2026, 21:22 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de abr. de 2026, 21:22 UTC

Conversa de Mercado

Moody's Downgrades Belgium to A1 -- Market Talk

17 de abr. de 2026, 20:52 UTC

Ganhos

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Ganhos
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

17 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

17 de abr. de 2026, 20:29 UTC

Ganhos

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 de abr. de 2026, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 de abr. de 2026, 19:34 UTC

Conversa de Mercado
Ganhos
Aquisições, Fusões, Aquisições de Empresas

Global Equities Roundup: Market Talk

17 de abr. de 2026, 19:34 UTC

Conversa de Mercado
Ganhos
Aquisições, Fusões, Aquisições de Empresas

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 de abr. de 2026, 19:31 UTC

Conversa de Mercado
Notícias Principais

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 de abr. de 2026, 19:26 UTC

Conversa de Mercado

U.S. Natural Gas Futures Edge Up -- Market Talk

17 de abr. de 2026, 19:21 UTC

Conversa de Mercado

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 de abr. de 2026, 19:15 UTC

Conversa de Mercado

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 de abr. de 2026, 19:07 UTC

Conversa de Mercado

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 de abr. de 2026, 18:57 UTC

Notícias Principais

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 de abr. de 2026, 18:53 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 de abr. de 2026, 18:53 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB 2026 Rev Guidance Unchanged

17 de abr. de 2026, 18:52 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 de abr. de 2026, 18:52 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 de abr. de 2026, 18:14 UTC

Conversa de Mercado
Notícias Principais

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 de abr. de 2026, 18:00 UTC

Notícias Principais

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 de abr. de 2026, 18:00 UTC

Notícias Principais

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 de abr. de 2026, 17:31 UTC

Conversa de Mercado
Notícias Principais

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 de abr. de 2026, 17:26 UTC

Conversa de Mercado
Ganhos

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Comparação entre Pares

Variação de preço

Prestige Consumer Healthcare Previsão

Preço-alvo

By TipRanks

40.84% parte superior

Previsão para 12 meses

Média 81.87 USD  40.84%

Máximo 93.624 USD

Mínimo 66 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Prestige Consumer Healthcare - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

4

Comprar

1

Manter

0

Vender

Sentimento

By Acuity

150 / 348 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and Debrox for ear wax removal. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; Dramamine for motion sickness relief; enemas and other laxative products under the Fleet brand name; Gaviscon for upset stomach; cough drops under the Luden's brand; Monistat for yeast infections in women; Nix for lice and parasite treatments; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; TheraTears for dry eyes; nasal saline sprays and washes under the Fess brand name; and Hydralyte for oral rehydration. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
help-icon Live chat